A Somerset man who was diagnosed with incurable blood cancer thanks the Taunton and Yeovil NHS teams who have been given an award for ...

Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma. Read why I maintain my hold rating for ACLX ...

The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

Researchers sought to determine whether patients who are functional high-risk had a worse prognosis even without having traditional high-risk features.

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple ...

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

Analyst John Newman from Canaccord Genuity maintained a Buy rating on Arcellx Inc (ACLX – Research Report) and keeping the price target at ...

The combination of talquetamab and teclistamab “warrants further investigation in patients with relapsed or refractory multiple myeloma,” according to researchers.